Revefenacin

Revefenacin
Clinical data
Trade names	Yupelri
Legal status
Legal status	US: ℞-only ;
Identifiers
CAS Number	864750-70-9;
PubChem CID	11753673;
DrugBank	11855;
ChemSpider	9928376;
UNII	G2AE2VE07O;
Chemical and physical data
Formula	C35H43N5O4
Molar mass	597.760 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;

Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]

References

"Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. November 9, 2018.
Heo, Young-A (2018). "Revefenacin: First Global Approval". Drugs. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
Donohue, James; Kerwin, Edward; Barnes, Chris; Moran, Edmund; Haumann, Brett; Pendyala, Srikanth; Crater, Glenn (2018). "Efficacy of Revefenacin, A Long-Acting Muscarinic Antagonist for Nebulized Therapy, in Copd Patients with Markers of More Severe Disease". Chest. 154 (4): 736A–737A. doi:10.1016/j.chest.2018.08.665.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. November 9, 2018.

[2] Heo, Young-A (2018). "Revefenacin: First Global Approval". Drugs. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.

[3] Donohue, James; Kerwin, Edward; Barnes, Chris; Moran, Edmund; Haumann, Brett; Pendyala, Srikanth; Crater, Glenn (2018). "Efficacy of Revefenacin, A Long-Acting Muscarinic Antagonist for Nebulized Therapy, in Copd Patients with Markers of More Severe Disease". Chest. 154 (4): 736A–737A. doi:10.1016/j.chest.2018.08.665.